Searched for
CAPECITABINE
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Sound businesses are the best antidote for volatility: 6 large- and mid-cap stocks with an upside potential of up to 30%The market hates uncertainty. Post the big reforms (GST and banking), the markets should have ideally been in upbeat mode this festive seas...
- One simple reason to own & trade them: 5 large-caps from different sectors with upside potential of up to 46%The rising stock price of a company does not mean that the business is strong. And a falling stock price does not mean that the business is...
- Focus beyond noise and uncertainty of tariff war: 6 Large-cap stocks with an upside potential of up to 42%The coming week will see statements from different parts of the world on the tariff war unleashed by US President Trump. And these will mak...
- Pharma stocks: With headwinds of uncertainty over, will they outperform? 7 stocks with an upside potential of up to 43%When it is Trump, logic usually flies out of the window. There is, indeed, little that is logical about the reciprocal tariffs he has annou...
- This time tailwinds for good and long term: 5 midcap pharma stocks where probably management has learnt the lessonPharma is one sector, where literally every company in the sector has gone through a phase where it is forced to have a look at its own bus...
- On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mi...
- Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in USThe product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (U...
- Smallcap Hunters: API plans make Shivalik Rasayan valuations look very compellingThe company’s core business of pesticides has steadily been doing around Rs 50 crore sales.
- Hetero launches generic breast cancer treatment drug in IndiaDrug firm Hetero Friday said it has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in th...
- Cipla arm secures marketing rights for cancer drug in USCipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.
- Divi’s Laboratories nosedives 20%, hits 52-week low on USFDA’s import alertIn a filing to BSE, the drug marker said that the USFDA has exempted the company from making ten drugs.
- Dr Reddy's in bear grip on adverse USFDA report, stock may fall 7-8%Open interest in Dr Reddy's futures rose 16% as short positions were built and was the highest since July 2007, while in the cash market, t...
- NPPA invites comments on Tata Memorial list of cancer drugs"(this is) on revision of NLEM 2011 with respect to addition/ deletion of drugs relating to oncology from price control and affordability a...
- Government panel moots clinical trial waiver for two cancer drugsThe two medicines - Aflibercept and Trastuzumab emtansine - are used in treatment of metastatic colorectal cancer and metastatic breast can...
- Intas settles patent litigation with Hoffmann-La Roche for capecitabine tabletAhmedabad-based drug maker, Intas Pharmaceuticals Ltd and its US-based wholly owned subsidiary Accord Healthcare Inc. has entered into a se...
- Cipla slashes prices of 3 cancer drug by up to 63%The company said on Thursday that its lung cancer drug Erlocip would cost Rs 9,900 for 30 tablets instead of Rs 27,000 and Rs 3,700 for 10 ...
- Shilpa Medicare receives EU GMP approval from GermanyPharma company Shilpa Medicare on Friday said it has received European Union GMP approval from Germany for two of its manufacturing sites f...
Load More
